User profiles for "author:Samantha Hinsley"
Samantha HinsleyUniversity of Glasgow Verified email at glasgow.ac.uk Cited by 1569 |
Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial
Background The role of adjuvant bisphosphonates in early breast cancer is uncertain. We
therefore did a large randomised trial to investigate the effect of the adjuvant use of …
therefore did a large randomised trial to investigate the effect of the adjuvant use of …
Efficacy and safety of weekly paclitaxel plus vistusertib vs paclitaxel alone in patients with platinum-resistant ovarian high-grade serous carcinoma: the OCTOPUS …
S Banerjee, G Giannone, AR Clamp, DP Ennis… - JAMA …, 2023 - jamanetwork.com
Importance Patients with platinum-resistant or refractory ovarian high-grade serous
carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. Preclinical …
carcinoma (PR-HGSC) have a poor prognosis and few therapeutic options. Preclinical …
Development and validation of the gene expression predictor of high-grade serous ovarian carcinoma molecular SubTYPE (PrOTYPE)
Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian
cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification …
cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification …
Early phase clinical trials extension to guidelines for the content of statistical analysis plans
This paper reports guidelines for the content of statistical analysis plans for early phase
clinical trials, ensuring specification of the minimum reporting analysis requirements, by …
clinical trials, ensuring specification of the minimum reporting analysis requirements, by …
A randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma …
436 Background: A subset of mUC exhibits a DNA repair deficiency (DRD) phenotype
predicting benefit from platinum based chemotherapy (PBC). We hypothesised that switch …
predicting benefit from platinum based chemotherapy (PBC). We hypothesised that switch …
[HTML][HTML] A randomized, double-blind, biomarker-selected, phase II clinical trial of maintenance poly ADP-ribose polymerase inhibition with rucaparib following …
PURPOSE A DNA repair deficiency (DRD) phenotype exists within a subset of metastatic
urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We …
urothelial carcinomas (mUC) predicting benefit from platinum-based chemotherapy. We …
Associations between serum bone biomarkers in early breast cancer and development of bone metastasis: results from the AZURE (BIG01/04) trial
J Brown, E Rathbone, S Hinsley… - JNCI: Journal of the …, 2018 - academic.oup.com
Background Adjuvant therapies can prevent/delay bone metastasis development in breast
cancer. We investigated whether serum bone turnover markers in early disease have clinical …
cancer. We investigated whether serum bone turnover markers in early disease have clinical …
[HTML][HTML] Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study
The fracture impact of adjuvant bisphosphonates in breast cancer is not defined with most
trials reporting changes in bone mineral density as a surrogate. The AZURE trial …
trials reporting changes in bone mineral density as a surrogate. The AZURE trial …
MUKnine OPTIMUM protocol: a screening study to identify high-risk patients with multiple myeloma suitable for novel treatment approaches combined with a phase II …
S Brown, D Sherratt, S Hinsley, L Flanagan… - BMJ open, 2021 - bmjopen.bmj.com
Introduction Multiple myeloma (MM) is a plasma cell tumour with over 5800 new cases each
year in the UK. The introduction of biological therapies has improved outcomes for the …
year in the UK. The introduction of biological therapies has improved outcomes for the …
[HTML][HTML] CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
GM Walls, JB Oughton, AJ Chalmers, S Brown… - Clinical and translational …, 2020 - Elsevier
Lung cancer is the leading cause of cancer mortality worldwide and most patients are
unsuitable for 'gold standard'treatment, which is concurrent chemoradiotherapy …
unsuitable for 'gold standard'treatment, which is concurrent chemoradiotherapy …